Related Experiment Videos
Emerging treatments in chronic hepatitis B
Stephanos J Hadziyannis1, George V Papatheodoridis
1Henry Dunant Hospital, Department of Medicine and Hepatology, 107 Messogion Avenue, Athens 11526, Greece. hadziyannis@ath.forthnet.gr
Expert Opinion on Emerging Drugs
|December 2, 2004
Summary
Current chronic hepatitis B treatments offer limited sustained off-therapy responses. Long-term maintenance with safe, low-resistance antiviral agents is the most realistic future option for patients.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B management has advanced, yet current therapies (IFN-alpha, lamivudine, adefovir dipivoxil) rarely yield sustained off-therapy responses.
- The need for more effective treatments for chronic hepatitis B is significant due to limitations of existing agents.
Purpose of the Study:
- To review newer agents for chronic hepatitis B treatment.
- To evaluate the efficacy and potential of emerging antiviral and immunomodulatory therapies.
- To identify the most promising future therapeutic strategies for chronic hepatitis B.
Main Methods:
- Review of current and emerging therapeutic agents for chronic hepatitis B.
- Analysis of clinical data on pegylated interferon-alpha(2a), entecavir, and telbivudine.
- Assessment of preliminary data for immunomodulatory and combination therapies.
Main Results:
- Pegylated interferon-alpha(2a) shows improved efficacy over lamivudine and standard interferon-alpha.
- Newer antivirals like entecavir and telbivudine demonstrate initial effectiveness, but long-term off-therapy responses are undetermined.
- Monotherapies with immunomodulatory agents and combination therapies have yielded disappointing preliminary results.
Conclusions:
- Pegylated interferon-alpha(2a) is a promising upcoming treatment for chronic hepatitis B.
- Long-term maintenance therapy with well-tolerated antiviral agents having low resistance rates is the most viable future strategy for most chronic hepatitis B patients.